Shapiro, Michael D.

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 1,094

Dual‐Energy X‐Ray Absorptiometry for Quantification of Visceral Fat

Kaul, S., Rothney, M. P., Peters, D. M., Wacker, W. K., Davis, C. E., Shapiro, M. D., & Ergun, D. L. (2012) · Obesity

Body Composition Measurement TechniquesBone health and osteoporosis research

Cited by 622

The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk

Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 608

PCSK9: From Basic Science Discoveries to Clinical Trials

Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 285

Ten things to know about ten cardiovascular disease risk factors

Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology

Cardiovascular Health and Risk FactorsHealth Promotion and Cardiovascular Prevention

Cited by 274

Apolipoproteins in vascular biology and atherosclerotic disease

Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 273

From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk

Shapiro, M. D., & Fazio, S. (2016) · Circulation Research

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 217

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Tardif, J.-C., Karwatowska-Prokopczuk, E., Amour, E. S., Ballantyne, C. M., Shapiro, M. D., Moriarty, P. M., Baum, S. J., Hurh, E., Bartlett, V. J., Kingsbury, J., et al. (2022) · European Heart Journal

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 210

Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology

Khera, A., Baum, S. J., Gluckman, T. J., Gulati, M., Martin, S. S., Michos, E. D., Navar, A. M., Taub, P. R., Toth, P. P., Virani, S. S., et al. (2020) · American Journal of Preventive Cardiology

COVID-19 and healthcare impactsHealth Promotion and Cardiovascular Prevention

Cited by 143

Recommended practices for computerized clinical decision support and knowledge management in community settings: a qualitative study

Ash, J. S., Sittig, D. F., Guappone, K. P., Dykstra, R. H., Richardson, J., Wright, A., Carpenter, J., McMullen, C., Shapiro, M., Bunce, A., et al. (2012) · BMC Medical Informatics and Decision Making

Electronic Health Records SystemsArtificial Intelligence in Healthcare and Education

Cited by 103

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab

Shapiro, M. D., Minnier, J., Tavori, H., Kassahun, H., Flower, A., Somaratne, R., & Fazio, S. (2019) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 70

Opportunistic Detection of Coronary Artery Calcium on Noncardiac Chest Computed Tomography: An Emerging Tool for Cardiovascular Disease Prevention: A Scientific Statement From the American Heart Association

Foraker, R., Sperling, L., Bratzke, L., Budoff, M., Leppert, M., Razavi, A. C., Rodriguez, F., Shapiro, M. D., Whelton, S., Wong, N. D., et al. (2025) · Circulation

Cardiac Imaging and DiagnosticsHealth Promotion and Cardiovascular Prevention

Cited by 44

Chylomicronemia syndrome: Familial or not?

Warden, B. A., Minnier, J., Duell, P. B., Fazio, S., & Shapiro, M. D. (2020) · Journal of Clinical Lipidology

Lipid metabolism and disordersLymphatic Disorders and Treatments

Cited by 34

Cardiac Magnetic Resonance Imaging for the Evaluation of Ventricular Function

Sarwar, A., Shapiro, M. D., Abbara, S., & Cury, R. C. (2008) · Seminars in Roentgenology

Cardiovascular Issues in PregnancyCongenital Heart Disease Studies

Cited by 26

Effect of PCSK9 inhibition on plasma levels of small dense low density lipoprotein-cholesterol and 7-ketocholesterol

Mahmood, T., Miles, J. R., Minnier, J., Tavori, H., DeBarber, A. E., Fazio, S., & Shapiro, M. D. (2024) · Journal of Clinical Lipidology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 9

Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies

Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 4

Developing Virtual Spanish-Language Resources: Exploring a Best Practices Model for Public Libraries

Shapiro, M. (2003) · OLA Quarterly

Library Science and AdministrationWeb and Library Services

Cited by 1